Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
The accelerated approval is supported by results from part 1 of the ESSENCE trial
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
Offering testing, treatment and support to help stop the spread of HIV and other infectious diseases
GL0034 administered once-weekly confirmed clinically meaningful weight loss and improved glucometabolic parameters over a 4-week treatment period in individuals with obesity
Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO
Subscribe To Our Newsletter & Stay Updated